Endo International plc Stock

Equities

ENDPQ

IE00BJ3V9050

Pharmaceuticals

Market Closed - OTC Markets 03:42:21 2024-04-18 pm EDT 5-day change 1st Jan Change
0.0006 USD 0.00% Intraday chart for Endo International plc +100.00% +20.00%
Sales 2022 2.32B Sales 2023 2.01B Capitalization 118K
Net income 2022 -2.92B Net income 2023 -2.45B EV / Sales 2022 2.97 x
Net Debt 2022 6.87B Net Debt 2023 7.41B EV / Sales 2023 3.68 x
P/E ratio 2022
-0.01 x
P/E ratio 2023
-
Employees 2,931
Yield 2022 *
-
Yield 2023
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart
1 week+100.00%
Current month+50.00%
1 month-25.00%
3 months+200.00%
6 months-93.33%
Current year+20.00%
More quotes
1 week
0.00
Extreme 0.0003
0.00
1 month
0.00
Extreme 0.0001
0.00
Current year
0.00
Extreme 0.0001
0.01
1 year
0.00
Extreme 0
0.08
3 years
0.00
Extreme 0
7.07
5 years
0.00
Extreme 0
10.89
10 years
0.00
Extreme 0
96.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 14-12-31
Director of Finance/CFO 54 06-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 78 14-01-31
Director/Board Member 77 14-02-27
Director/Board Member 54 21-02-16
More insiders
Date Price Change Volume
24-04-18 0.0006 0.00% 3,358
24-04-17 0.0006 -85.00% 618,662
24-04-16 0.004 +122.22% 1,666,609
24-04-15 0.0018 +500.00% 416,769
24-04-12 0.0003 0.00% 24,140

Delayed Quote OTC Markets, April 18, 2024 at 03:42 pm EDT

More quotes
Endo International plc is a specialty pharmaceutical company. The Company operates through four business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Its Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, NASCOBAL Nasal Spray, AVEED, QWO, PERCOCET, TESTOPEL and EDEX, among others. Its Sterile Injectables segment consists of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The Company’s Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays.
More about the company

Quarterly revenue - Rate of surprise